# Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and Adolescents

> **NCT01239485** · PHASE1 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 18 (estimated)

## Conditions studied

- Acute Leukemia

## Interventions

- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT01239485
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-11
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2013-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01239485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01239485, "Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and Adolescents". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01239485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*